

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period November 1 - 30, 2024

Supplementary Exhibit & Answers

Part 7, Question a. (Were any payments made on prepetition debt?):

The Debtors obtained post-petition financing consistent with the Interim Order Approving Motion to Approve Debtor In Possession Financing [Docket No. 103] and the Final Order (I) Authorizing the Debtors to Obtain Postpetition Financing, (II) Authorizing the Debtors to Use Cash Collateral, (III) Granting Liens and Providing Superpriority Administrative Expense Claims, (IV) Granting Adequate Protection, (V) Modifying Automatic Stay, and (VI) Granting Related Relief [Docket No. 248].

Part 7, Question c. (Were any payments made to or on behalf of insiders?):

Payments made on behalf of insiders include only regular salary and compensation to the Debtors' CEO, CFO, General Counsel, and/or independent directors.

Part 7, Question g. (Was there any postpetition borrowing, other than trade credit?):

The Debtors obtained post-petition financing consistent with the *Interim Order Approving Motion to Approve Debtor In Possession Financing* [Docket No. 103].

In re: Vyair Medical, Inc., et al.

24-11217 (BLS)

Statement of Cash Receipts and Disbursements

November 1 - 30, 2024

	Vyair Medical, Inc. (Consolidated)
Operating Receipts	
Collections	\$ 2,924,282
Total Operating Receipts	2,924,282
Operating Disbursements	
Trade Vendors	(5,081,179)
Payroll & Comissions	(2,609,643)
T&E Credit card	(124,154)
State and other taxes	(53,489)
Insurance	(335,019)
Customs Duty	(4,834)
Inter-company transfers	(142,635)
Total Operating Disbursements	(8,350,952)
Net Cash Flow from Operations	(5,426,670)
Non- Operating Receipts / (Disbursements)	
Other Non-Estate Receipts	300,000
Other Non-Estate Disbursements	(669,000)
Other Non-Operational	53,242,194
Total Non- Operating Receipts / (Disbursements)	53,542,194
Total Net Cash Flow	48,115,524
Restructuring Receipts/(Disbursements)	
DIP Draw	(26,250,000)
DIP Interest & Fees	(2,565,000)
Professional Fees	(2,764,413)
Sale Proceeds to Lenders Roll Up Loans	(13,435,000)
Sale Proceeds to First Lien Agent Fees	(1,463,162)
D&O, Critical Vendor, and Other Contingency	(133,750)
Total Restructuring Receipts/(Disbursements)	(46,611,325)
Liquidity	
Book Cash Balance - Start	14,614,023
Net Cash Flow (+/-)	835,199
Change in Outstanding ACH/Wire/Check Balance	77,457
Book Cash Balance - End	15,526,680

In re: Vyair Medical, Inc., et al.
24-11217 (BLS)
Income Statement
November 1 - 30, 2024

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	18	16	17	15	19	20	21	22	23	24	25	26	27	28
	Vyaire Medical, Inc.	Bird Products Corporation	Breathe US HoldCo, Inc.	Breathe US Holdings LP	EME Medical, Inc.	Revolutionary Medical Devices, Inc.	SensorMedics Corporation	VIASYS Holdings Inc.	VM Finance Sub, LLC	Vyaire Company	Vyaire Finance B.V.	Vyaire Financial Holdings LLC	Vyaire Holding Company	Vyaire Medical 202, Inc.	Vyaire Medical 203, Inc.	Vyaire Medical 205, Inc.	Vyaire Medical 206, Inc.	Vyaire Medical 211, Inc.	Vyaire Medical BR LLC	Vyaire Medical Capital LLC	Vyaire Medical Consumables LLC	Vyaire Medical International LLC	Vyaire Medical Payroll LLC	Vyaire Receivables LLC	Vyaire Respiratory Diagnostics LLC	Vyaire TSR MidCo, LLC	Vyaire TSR Sub, LLC	
Revenue																												
Third Party Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	(2,595)	\$ -	\$ -	660,289	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Intercompany Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Revenue																(2,595)	-	660,289	-	-	-	-	-	-	-	-	-	-
COGS																												
Standard COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41,181	-	-	-	-	-	-	-	-	-	
IC COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
DCOS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,209	-	-	-	-	-	-	-	-	-	
Total COGS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48,390	-	-	-	-	-	-	-	-	-	
Operating Expenses																												
Salaries & Benefits	438,345	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	123,393	-	-	-	-	-	-	-	-	-	
Other Operating Expenses	26,992,474	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,429	-	1,230,607	-	-	-	-	-	-	-	-	-	
Total Operating Expenses	27,430,818	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,429	-	1,354,000	-	-	-	-	-	-	-	-	-	
Non-Operating Expenses																												
Amortizations	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Currency	(963,710)	-	-	-	-	-	-	-	-	-	(0)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Income Tax Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Net Interest	2,621	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Non-recurring charges	157,759	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Other Income Expense	(423,027,283)	-	-	-	-	-	-	-	-	-	(111,905,675)	-	-	-	-	(2)	-	-	-	-	-	-	-	-	-	-	-	
Disposal of Business	(52,247,564)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Restructuring	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
Total Non-Operating Expenses	(476,078,177)	-	-	-	-	-	-	-	-	-	(111,905,675)	-	-	-	-	(2)	-	-	-	-	-	-	-	-	-	-	-	
Net Income	\$ 448,647,358	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 111,905,675	\$ -	\$ -	\$ -	\$ -	(12,022)	\$ -	\$ -	(742,101)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	

In re: Vyair Medical, Inc., et al.

Case No.: 24-11217 (BLS)
Reporting Period 11/1/2024 - 11/30/2024

Bank Reconciliations

The Debtors hereby submit this attestation regarding bank account reconciliations in lieu of providing copies of bank statements, bank reconciliations and journal entries.

The Debtors' standard practice is to ensure that bank reconciliations are completed before closing the books each reporting period. I attest that each of the Debtors' bank accounts has been reconciled in accordance with their standard practices.

/s/ David Barse
Signature of Authorized Individual

12/23/2024
Date

David Barse
Printed Name of Authorized Individual

Plan Administrator
Title of Authorized Individual